M&A Class Action Firm Continues to Investigate Major Transactions for Shareholder Rights Monteverde & Associates PC is conducting investigations into the mergers involving VTYX, ALEX, RVYL, and FFWM, aiming to protect shareholder interests.

M&A Class Action Firm Continues to Investigate Major Transactions for Shareholder Rights #USA #New_York #Monteverde_Associates #ALEX #VTYX

JUST IN: ( NASDAQ: #VTYX ) Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?

Halper Sadeh LLC Invites VTYX, SNCY, and EKSO Shareholders to Discuss Legal Rights Halper Sadeh LLC encourages shareholders of Ventyx Biosciences, Sun Country Airlines, and EKSO Bionics to explore their rights and options regarding recent corporate actions.

Halper Sadeh LLC Invites VTYX, SNCY, and EKSO Shareholders to Discuss Legal Rights #United_States #New_York #Halper_Sadeh #VTYX #SNCY

Most Searched, Thursday January 8, 2026 – Crystal Equity Research

Most searched small-cap stocks, Thu Jan 8th - #MLTX #RZLV #SHCO #RR #VTYX #ELME #ACRV #ACON #SERV #DNN #NEOG #TE #FLYX #TLRY #SG #RDW #IDR #HYMC #CRML #AEVA - More: crystalequityresearch.com/most-searche... #smallcap

NEWS: ( NASDAQ: #VTYX ) Perform Recommendation Issued On VTYX By Oppenheimer

Pomerantz Law Firm Launches Investigation for Ventyx Biosciences Investors Amid Claims of Securities Fraud Pomerantz LLP is probing Ventyx Biosciences following a significant stock drop attributed to a shift in clinical trial timelines. Investors may have been affected.

Pomerantz Law Firm Launches Investigation for Ventyx Biosciences Investors Amid Claims of Securities Fraud #United_States #New_York #Pomerantz_LLP #Ventyx_Biosciences #VTYX

Most Searched, Wednesday January 7, 2026 – Crystal Equity Research

Most searched small-cap stocks, Wed Jan 7th - #INVX #RXRX #BITF #BBAI #CLSK #LAC #CDIO #UWMC #RR #GLUE #VTYX #MNTS #HOUS #UAMY #ERAS #DNN #CRML #RZLV #NVVE #PLUG - More: crystalequityresearch.com/most-searche... - #smallcap

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Lilly (NYSE: LLY) agreed to acquire clinical-stage Ventyx Biosciences for $14.00 per share in an all-cash deal valued at approximately $1.2 billion. The acquisition adds Ventyx's small-molecule pipeline, including class-leading NLRP3 inhibitors aimed at oral treatments for inflammatory-mediated diseases across cardiometabolic, neurodegenerative and inflammatory disorders. The deal carries an approximate 62% premium to Ventyx's 30-day VWAP through Jan. 5, 2026, is not subject to financing, and is expected to close in the first half of 2026 pending shareholder and regulatory approvals.

#LLY #VTYX Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

www.stocktitan.net/news/LLY/lilly-to-acquir...

Shares in small biotech company Ventyx soared 70%. How is this related to Eli Lilly? – Oninvest Shares of Ventyx Biosciences, a small-cap developer of anti-inflammatory drugs, rose nearly 70% in morning trading on January 7. The growth was driven by a report in The Wall Street Journal that pharm...

📈 #VTYX jumped nearly 70% in morning trading today after The WSJ reported Eli Lilly is in talks to acquire the company. The deal could be worth over $1 billion, sources said. Details on the company and its pipeline 👇 en.oninvest.com/article/shar...

📢 Stocks Trending NOW: #SNDK #MU #VTYX #ISRG #GME #GLUE #MBLY #LUCY #ASBP #AMOD

Leading Indicators, Tuesday January 6, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend according to average directional index, Tue Jan 6th - #WPRT #VTYX #TRNS #SELF #REE #MGNX #LVRO #KNDI #JRSH #INMD #HYFM #GILT #CCCX #ABUS #MTX #LZM #HUN #DCO #CANG - More: crystalequityresearch.com/leading-indi... - #smallcap

Pomerantz Law Firm Looks Into Allegations Against Ventyx Biosciences, Inc. Amid Stock Price Drop Pomerantz LLP is investigating potential claims relating to Ventyx Biosciences, Inc., including possible unlawful business practices impacting investors.

Pomerantz Law Firm Looks Into Allegations Against Ventyx Biosciences, Inc. Amid Stock Price Drop #USA #New_York #Pomerantz_LLP #Ventyx_Biosciences #VTYX

BREAKING NEWS: ( NASDAQ: #VTYX ) Ventyx Provides Clinical and Corporate Updates

Ventyx Provides Clinical and Corporate Updates Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development plan Interim

#VTYX Ventyx Provides Clinical and Corporate Updates

www.stocktitan.net/news/VTYX/ventyx-provide...

Just In: ( NASDAQ: #VTYX ) Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

NEWS: ( NASDAQ: #VTYX ) Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Just In: ( NASDAQ: #VTYX ) Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress Ventyx Biosciences (Nasdaq: VTYX) reported Q3 2025 results and pipeline progress on Nov 6, 2025. Key clinical readouts included positive Phase 2 data for the CNS‑penetrant NLRP3 inhibitor VTX3232 (hsCRP ~80% reduction; IL‑6, Lp(a), fibrinogen, ESR reductions; CSF and plasma exposures ≥3× IC90) and positive Phase 2a biomarker data in early Parkinson’s disease with biomarker and symptom improvements. Topline results for VTX2735 in recurrent pericarditis are expected Q4 2025. Cash, cash equivalents and marketable securities were $192.6M as of Sept 30, 2025, expected to fund operations into at least H2 2026.

#VTYX Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

www.stocktitan.net/news/VTYX/ventyx-bioscie...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OKLO, #HIMS, #CYBN, #CRWV, #VTYX

#OptionFlow #OptionsTrading #Trading

Most Searched, Thursday October 23, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Oct 23rd - #DVLT #TNGX #RXRX #LAES #ONDS #SGBX #NVTS #DNN #AREB #TE #VTYX #WRD #VLRS #UAMY #INOD #BYND #BTCS #BORR #DNUT #APP - More: crystalequityresearch.com/most-searche... - #smallcap

📢 Stocks Trending NOW: #IONQ #IBM #TSLA #QBTS #RGTI #VTYX #FCX #AAL #QUBT #HON

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular

#VTYX Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

www.stocktitan.net/news/VTYX/ventyx-bioscie...

Trade Alerts, Wednesday October 1, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading Wed Oct 1st - #PALI #NVA #GLXG #VTYX #RVYL #LGHL #CLLS #LAC - More: crystalequityresearch.com/trade-alerts... - #smallcap

BREAKING NEWS: ( NASDAQ: #VTYX ) Expected earnings - Ventyx Biosciences Inc.

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress Ventyx Biosciences (NASDAQ:VTYX) reported Q2 2025 financial results and pipeline updates, highlighting positive developments across its drug portfolio. The company reported a strong cash position of $209.0 million, expected to fund operations into H2 2026. Key highlights include positive Phase 2a biomarker data for VTX3232 in Parkinson's disease, demonstrating safety, high drug exposure, and potent NLRP3 biomarker suppression. Two Phase 2 studies are expected to yield results in Q4 2025: VTX2735 for recurrent pericarditis and VTX3232 for obesity with cardiometabolic risk factors. The company's Q2 2025 financials showed reduced losses, with net loss decreasing to $27.0 million from $32.0 million year-over-year. R&D expenses decreased to $22.3 million from $27.8 million in Q2 2024.

#VTYX Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

www.stocktitan.net/news/VTYX/ventyx-bioscie...

News; ( NASDAQ: #VTYX ) Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease Ventyx Biosciences (VTYX) announced positive top-line results from its Phase 2a study of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in early-stage Parkinson's disease patients. The trial met its primary objective, demonstrating safety and tolerability with no drug-related adverse events. The 28-day study of 40mg daily oral dose in 10 patients showed significant pharmacokinetic and pharmacodynamic success, with drug levels maintaining above IC90 for 24 hours. VTX3232 demonstrated clear target engagement by reducing NLRP3-related biomarkers in both plasma and CSF. Notably, patients showed statistically significant improvements in motor and non-motor symptoms measured by MDS-UPDRS Parts I, II, and III. The company plans to advance to a placebo-controlled Phase 2 trial in Parkinson's disease and potentially expand into Alzheimer's disease treatment.

#VTYX Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

www.stocktitan.net/news/VTYX/ventyx-bioscie...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Jun 5th - #RXRX #EXK #PL #WULF #ZENA #VTYX #XMTR #WINT #VLRS #UEC #QUBT #NVTS #MULN #MODV #LGMK #LEU #HUT #CRCL #BTCB #APLD - More: crystalequityresearch.com/SmCpStr/ - #smallcap